Background:
Paclitaxel and spirulina when administered as nanoparticles, are potentially
useful.
Methods:
Nanoformualtions of Paclitaxel and Spirulina for gastric cancer were formulated and optimized
with Central composite rotatable design (CCRD) using Response surface methodology
(RSM).
Results:
The significant findings were the optimal formulation of polymer concentration 48 mg,
surfactant concentration 45% and stirring time of 60 min gave rise to the EE of (98.12 ± 1.3)%, DL
of (15.61 ± 1.9)%, mean diameter of (198 ± 4.7) nm. The release of paclitaxel and spirulina from the
nanoparticle matrix at pH 6.2 was almost 45% and 80% in 5 h and 120 h, respectively. The oral
bioavailability for the paclitaxel spirulina nanoparticles developed is 24.0% at 10 mg/kg paclitaxel
dose, which is 10 times of that for oral pure paclitaxel. The results suggest that RSM-CCRD could
efficiently be applied for the modeling of nanoparticles. The paclitaxel and spirulina release rate in
the tumor cells may be higher than in normal cells. Paclitaxel spirulina nanoparticle formulation may
have higher bioavailability and longer sustainable therapeutic time as compared with pure paclitaxel.
Conclusion:
Paclitaxel-Spirulina co-loaded nanoparticles could be effectively useful in gastric cancer
as chemotherapeutic formulation.
